–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only ...

Before diving into the highlights '24, we did put on the 20 years Molecular Partners logo because it is our ... This number is clearly volatile by design. And this year, I think we, as I said ...

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

See how the iconic logo has changed from GTA 1 to GTA 6 as we explore the visual history of the Grand Theft Auto series here.

The Louisville Bats launched a new secondary logo last month ahead of the team's 25th season of baseball at Louisville ...

Shares of Sanofi India gained above 4 percent in early trade on February 28 following its Q4FY25 earnings, as the company reported healthy revenue growth even as profitability faced some ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...